As we have detailed in prior posts (most recently here), one of the key securities class action litigation filing trends this year has been the emergence of a host of securities suits alleging various types of market manipulation, including, in particular pump-and-dump schemes. In the latest example of this trend, on September 10, 2026, a plaintiff shareholder filed a securities lawsuit against the Singapore-based Ryde Group (RYDE) in a complaint alleging that the defendants engaged in a pump and dump scheme. This new lawsuit is the 15th market manipulation complaint to be filed so far this year.
The RYDE lawsuit is noteworthy because it stems from an alleged pump-and-dump scheme that occurred nearly two years ago, highlighting the potential litigation tail associated with these events. The allegations also closely resemble those in other recent market-manipulation suits, including the complaint filed against Ostin Technology Group Co., Ltd. (OST), involving a low-float issuer whose stock allegedly was inflated through coordinated promotional activity before collapsing.
As discussed below, the Ryde lawsuit highlights several considerations for D&O insurers and underwriters as market-manipulation litigation continues to evolve.
A copy of the complaint can be found here.
The Lawsuit
On September 10, 2026, the securities class action complaint was filed in the United States District Court for the Southern District of New York against RYDE and several related defendants, including current and former executives as well as certain third parties associated with the company’s public offering.
The complaint alleges that following its March 2024 IPO at $4.00 per share, RYDE’s stock price climbed to as high as $22.49 despite the absence of corresponding business developments that would justify the increase. According to the complaint, the stock-price surge resulted from a coordinated promotional campaign conducted through social media and online messaging platforms, where individuals allegedly posing as investment professionals encouraged retail investors to purchase RYDE shares.
According to the complaint, the alleged scheme unraveled on September 11, 2024, when the company’s share price fell approximately 75% in a single trading day. The plaintiffs contend that investors suffered losses when the market discovered that the stock’s dramatic appreciation had been driven by promotional activity rather than the company’s underlying business performance.
Discussion
The allegations in the RYDE securities class action are consistent with a broader market-manipulation trend that The D&O Diary has tracked throughout 2026 involving foreign-domiciled, low-float microcap issuers listed on U.S. exchanges. Many of these cases involve companies that experience extraordinary stock-price increases seemingly disconnected from underlying business fundamentals, followed by rapid and severe price collapses. As the number of these lawsuits has increased over the past year, the trend has drawn growing attention from plaintiffs’ attorneys and regulators.
The RYDE complaint also bears a particularly close resemblance to the litigation involving OST expressly references OST, as well as other issuers that allegedly exhibited similar trading patterns and ownership structures. Like OST, Ryde is alleged to have experienced a dramatic stock-price increase followed by a sharp collapse, with plaintiffs attributing the trading activity to coordinated promotional efforts rather than company performance. Indeed, the complaint’s extensive reliance on parallels to OST and other issuers highlights a growing trend in which plaintiffs’ firms are not merely pursuing individual securities claims but effectively policing perceived market abuses in a manner that increasingly resembles regulatory enforcement.
In addition, the Ryde action illustrates the potentially long-tail nature of these claims. The stock-price collapse at the center of the complaint occurred in September 2024, yet the lawsuit was not filed until September 2026. This delayed-filing pattern has become an increasingly common feature of these cases, with plaintiffs apparently refraining from filing immediately after a stock-price drop or trading halt and instead waiting for subsequent developments that may provide support for allegations of a coordinated market-manipulation scheme. For D&O underwriters, these cases demonstrate that alleged market-manipulation events can create litigation exposure long after the underlying trading activity has ceased.
Furthermore, the complaint takes an expansive approach to the defendants it seeks to hold liable. In addition to RYDE’s issuer and its executives, the lawsuit seeks to impose liability on several parties involved in the company’s IPO and public-company operations. The inclusion of these additional defendants broadens the range of insurers potentially implicated by the litigation, extending the potential exposure beyond the company’s D&O program. Whether these liability theories ultimately succeed remains to be seen, but the expanded party roster may increase D&O underwriting exposure.
Finally, the RYDE securities case arrives at a time when concerns surrounding small-cap and microcap issuers appear to be receiving greater attention. Reportedly, there has been a significant increase in direct listings and other pathways to the public markets for smaller companies in 2026. This could create a larger population of issuers that may share some of the characteristics frequently cited in these market-manipulation lawsuits, including foreign domicile, concentrated ownership, and limited public floats. Against that backdrop, D&O underwriters may want to pay particular attention to these and other issuer attributes that have repeatedly appeared in the complaints.
From a D&O perspective, the Ryde lawsuit underscores that foreign-domiciled, low-float issuers listed on U.S. exchanges continue to present a significant source of securities litigation risk. As plaintiffs’ lawyers continue to develop and refine their theories in these cases, D&O insurers and underwriters will be watching closely to assess the implications for underwriting, claims activity, and future litigation risk.